A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma
Michael J. Dennis(University of San Diego), Kathryn A. Gold(University of California San Diego), Assuntina G. Sacco(University of California San Diego), Karen Messer(University of California, San Diego), Yuchen Qi(University of California, San Diego), Ruifeng Chen(University of California, San Diego), Ezra E.W. Cohen(University of California San Diego), Emily Pittman(University of California, San Diego), Julie Bykowski(University of California San Diego)
Cited by 21
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
|The Lancet Oncology|2015|391
Clinical Practice Guideline: Ménière’s Disease
|Otolaryngology|2020|301